The purpose of this research study is to determine if the study drug, flotetuzumab, is safe
and tolerable when given to participants with acute myeloid leukemia (AML) that has relapsed
after transplant.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins